Healthy volunteers Not Applicable
Conditions
Interventions
Participants were randomly assigned to either a fish oil or a placebo supplement in a juice-based beverage form supplied by Smartfish Nutrition Ltd. The supplements were ingested for 6 weeks. The fish
Sponsors
Smartfish Nutrition Ltd.
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Male aged 18 - 35 years. 2. Resistance training for at least two times per week for 6 months prior to the study. 3. Healthy (no known metabolic diseases or eating disorders as determined by our health questionnaire).
Exclusion criteria
Exclusion criteria: 1. Currently supplementing with fish oil. 2. Currently taking medication that would provide inaccurate results as determined by our health questionnaire. 3. Involved in another clinical trial. 4. Substance abuse within the last year. 5. Eating disorder within the last year. 6. Metabolic disorders. 7. Employee of the sponsor, study site, or members of their immediate family. 8. Smoke regularly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at weeks 1 (day 7), 4 (day 27) and 6 (day 41): 1. Weight loss 2. Body composition measured using a narrowed fan-beamed dual-energy x-ray absorptiometry (iDXA GE Healthcare) with analysis performed using GE Encore 13.40.038 Software (GE Healthcare) 3. Exercise performance during a two week period of energy restriction (60% of normal intake) measured using three exercises: 3.1 Single leg isokinetic/eccentric maximum voluntary contraction (MVC) of the knee flexors using an isokinetic dynamometer 3.2 Unilateral 1RM for leg extension and leg press on a fixed resistance machine 3.3 Muscular endurance (as many repetitions as possible on leg extension and leg press exercises, with resistance set at 60% of individual baseline 1RM). | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at weeks 1 (day 7), 4 (day 27) and 6 (day 41): 1. Fat mass measured using a narrowed fan-beamed dual-energy x-ray absorptiometry ( iDXA GE Healthcare) with analysis performed using GE Encore 13.40.038 Software (GE Healthcare) 2. Fat-free mass measured using a narrowed fan-beamed dual-energy x-ray absorptiometry (iDXA GE Healthcare) with analysis performed using GE Encore 13.40.038 Software (GE Healthcare) 3. Bone mass measured using a narrowed fan-beamed dual-energy x-ray absorptiometry (iDXA GE Healthcare) with analysis performed using GE Encore 13.40.038 Software (GE Healthcare) 4. Overall body fat percentage measured using a narrowed fan-beamed dual-energy x-ray absorptiometry (iDXA GE Healthcare) with analysis performed using GE Encore 13.40.038 Software (GE Healthcare) 5. Resting energy expenditure measured using indirect calorimetry (Oxycon Pro; Cardinal Health) 6. Muscle anabolic signalling (the capacity for muscle to make new proteins) measured using western blot analysis 7. Muscle catabolic signalling (the signals driving the breakdown of muscle proteins by the body) measured using western blot analysis 8. mRNA expression (the expression of certain genes associated with muscle building and breakdown) during weight loss measured using western blot analysis. | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactJordan Philpott
Outcome results
None listed